Dihydrofolate reductase inhibitors as antibacterial agents.
about
Gene copy-number polymorphism caused by retrotransposition in humansLong-range pseudoknot interactions dictate the regulatory response in the tetrahydrofolate riboswitchStructure-Guided Development of Efficacious Antifungal Agents Targeting Candida glabrata Dihydrofolate ReductaseComplex structure of Bacillus subtilis RibG: the reduction mechanism during riboflavin biosynthesisIncreased hydrophobic interactions of iclaprim with Staphylococcus aureus dihydrofolate reductase are responsible for the increase in affinity and antibacterial activityCrystal Structure of Bacillus anthracis Dihydrofolate Reductase with the Dihydrophthalazine-Based Trimethoprim Derivative RAB1 Provides a Structural Explanation of Potency and SelectivityX-ray structure of the ternary MTX.NADPH complex of the anthrax dihydrofolate reductase: a pharmacophore for dual-site inhibitor designDesign, Synthesis, and X-ray Crystal Structure of Classical and Nonclassical 2-Amino-4-oxo-5-substituted-6-ethylthieno[2,3- d ]pyrimidines as Dual Thymidylate Synthase and Dihydrofolate Reductase Inhibitors and as Potential Antitumor AgentsKinetic and Structural Characterization of Dihydrofolate Reductase from Streptococcus pneumoniaeToward New Therapeutics for Skin and Soft Tissue Infections: Propargyl-Linked Antifolates Are Potent Inhibitors of MRSA and Streptococcus pyogenesAssessment of Pseudomonas aeruginosa N5,N10-Methylenetetrahydrofolate Dehydrogenase - Cyclohydrolase as a Potential Antibacterial Drug TargetThe Structure and Competitive Substrate Inhibition of Dihydrofolate Reductase from Enterococcus faecalis Reveal Restrictions to Cofactor DockingStructural genomics for drug design against the pathogen Coxiella burnetiiMycobacterium tuberculosis folate metabolism and the mechanistic basis for para-aminosalicylic acid susceptibility and resistanceHigh-throughput screening and sensitized bacteria identify an M. tuberculosis dihydrofolate reductase inhibitor with whole cell activityAn innovative strategy for dual inhibitor design and its application in dual inhibition of human thymidylate synthase and dihydrofolate reductase enzymesNewer antibacterial drugs for a new century.Discovery of an acyclic nucleoside phosphonate that inhibits Mycobacterium tuberculosis ThyX based on the binding mode of a 5-alkynyl substrate analogue.Parallel multiplicative target screening against divergent bacterial replicases: identification of specific inhibitors with broad spectrum potentialPostgenomic strategies in antibacterial drug discovery.Challenges of antibacterial discoveryToward the design of mutation-resistant enzyme inhibitors: further evaluation of the substrate envelope hypothesis.High-frequency transposition for determining antibacterial mode of action.Activity and interactions of antibiotic and phytochemical combinations against Pseudomonas aeruginosa in vitro.Aminobenzoates as building blocks for natural product assembly lines.Crystal structures of Klebsiella pneumoniae dihydrofolate reductase bound to propargyl-linked antifolates reveal features for potency and selectivity.Iclaprim.Pyruvate kinase isoform expression alters nucleotide synthesis to impact cell proliferationBreaking the rules: bacteria that use several DNA polymerase IIIs.Current and novel antibiotics against resistant Gram-positive bacteriaOrphan toxin OrtT (YdcX) of Escherichia coli reduces growth during the stringent response.Design and Synthesis of a Focused Library of Diamino Triazines as Potential Mycobacterium tuberculosis DHFR InhibitorsProspective screening of novel antibacterial inhibitors of dihydrofolate reductase for mutational resistanceSynthesis and biological activity of substituted 2,4-diaminopyrimidines that inhibit Bacillus anthracis.New Structural Templates for Clinically Validated and Novel Targets in Antimicrobial Drug Research and Development.Metabolism and Disposition of Aditoprim in Swine, Broilers, Carp and Rats.Investigational treatments for postoperative surgical site infections.Pharmacologic options for CNS infections caused by resistant Gram-positive organisms.Advances in MRSA drug discovery: where are we and where do we need to be?In vitro activity of Iclaprim against respiratory and bacteremic isolates of Streptococcus pneumoniae.
P2860
Q21144898-7B080F03-47EB-42E5-A453-73A7D57E28C3Q24601192-942DE3D1-AB66-4A21-9277-8FE6DCF99538Q27652249-C35D4573-439A-4D24-82F4-C505BB32F88FQ27652776-3FF9B831-D9FB-4F9F-A679-6DE92D6E79CBQ27653751-0C8C3C2A-350B-42DD-8164-5BA1B364EA31Q27654731-A71EE973-E0E2-4056-94AE-628D92586C9AQ27654896-EA89FC92-1C86-484A-8758-9209A59BED8CQ27657240-714744A7-2F2E-425C-8023-94C46D80EB30Q27658393-FFD16521-DABF-4734-881A-25ABDD3D9D7EQ27677355-A7690AC8-3BF0-4E4A-956F-1FCDD9B2F926Q27678891-45DA02BA-FEF3-4B1B-A383-A258ED2D7297Q27681580-DE886CF2-4996-4B76-AD0D-8A07AD33C8C9Q27700949-F7F8CEEF-67F1-493A-A0C2-8C5D0F54DCD4Q28082718-41ECA10D-31C5-47A1-B80B-00F09D07DB9AQ28480878-300067EC-4920-4619-B68F-6783A644C362Q28486030-BA6D7A35-25CB-4631-85F6-BBE9B9501D5FQ30433333-F5414720-4269-4C33-9FCE-FA2D12DECA2FQ30654112-F5AA6CCD-146F-4F42-83CB-47893C3708DFQ33534400-6DB9B594-D875-47AA-BDD0-124AE3226654Q33745572-7AA86D1F-4A3E-4328-BB7A-AD58C36F1491Q33793074-B3A177D4-59B1-4DE0-A151-5C6F5CD4A1FCQ33815097-691E3026-74DD-4E44-AB33-9A4641712109Q34011008-DE54FE66-9AC5-4EB8-B455-FFC9C88819D7Q34187311-77197314-F34C-4D55-BBA7-1587AA88C548Q34230699-10F9A6C5-C08E-4E10-AD9B-A4E1C3E772EAQ34597438-4F1719F3-A9BD-4214-B438-05AE0709CFF6Q34666376-2DF90C86-4734-4B8D-9364-D95E27F34C8CQ34898927-B5CE7926-0777-4A98-907E-8D646B33C31BQ34953383-F7134DCB-4305-4ADD-9BE4-ECA289F06998Q35026521-205541C5-5629-44B5-BF04-A3457C8F0B7AQ35131534-21DB2EEA-8BB7-40ED-84B8-B09AB07CB7A2Q35855294-830476C9-8EBB-4334-AF1D-FDEC5FD1669EQ36086509-599F36C4-73AA-4658-82B4-5ABE5B866479Q36129198-7B6DE129-13BC-43FA-BE87-E2B4AEA54D71Q36153263-71CE9178-FEB8-4692-814B-D9A6FB70409BQ36536274-4793BC14-5946-4CA2-B94A-FB6394B73BC5Q36715742-B841A992-C779-499B-ABB1-A490450A9C35Q37077629-FC4266E9-5F0A-43D5-B5B4-3039D599CF19Q37112508-673C6296-1581-46B3-8A05-54D160907CB0Q37144800-966AEF0A-B9B8-466B-9C08-F16718D37563
P2860
Dihydrofolate reductase inhibitors as antibacterial agents.
description
2005 nî lūn-bûn
@nan
2005 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Dihydrofolate reductase inhibitors as antibacterial agents.
@ast
Dihydrofolate reductase inhibitors as antibacterial agents.
@en
Dihydrofolate reductase inhibitors as antibacterial agents.
@nl
type
label
Dihydrofolate reductase inhibitors as antibacterial agents.
@ast
Dihydrofolate reductase inhibitors as antibacterial agents.
@en
Dihydrofolate reductase inhibitors as antibacterial agents.
@nl
prefLabel
Dihydrofolate reductase inhibitors as antibacterial agents.
@ast
Dihydrofolate reductase inhibitors as antibacterial agents.
@en
Dihydrofolate reductase inhibitors as antibacterial agents.
@nl
P2093
P1476
Dihydrofolate reductase inhibitors as antibacterial agents.
@en
P2093
Khalid Islam
Sergio Lociuro
Stephen Hawser
P304
P356
10.1016/J.BCP.2005.10.052
P407
P577
2005-12-13T00:00:00Z